scorecardresearch Skip to main content

More Life Sciences Headlines

Theseus lays off almost three-fourths of its staff

The Cambridge biotech is the latest biopharma firm in Massachusetts to slash its workforce in a prolonged industrywide shakeout that followed years of exuberant investment and growth.

EMD Serono headquarters plans to join biopharma cluster in Boston’s Seaport

The company will join more than two dozen life sciences companies, including Vertex and Eli Lilly, in the neighborhood.

Vacancy in Boston-area lab space climbs to 10-year high

A wave of projects that launched construction a few years ago when inventory was tight are now opening into a market that suddenly has little need for them.

kara miller | the big idea

‘You can’t cure cancer when you’re sitting in traffic’: The MBTA poses a problem for Mass. competitiveness

For a state itching to herald its technological prowess, workers’ inability to quickly get to offices, labs, hospitals, and universities has become an issue of competitiveness.

Judge upholds $24 million verdict against Thermo Fisher subsidiary that discriminated against worker with anxiety

US District Court Judge Leo T. Sorokin acknowledged that the sum was “remarkable” but said he had no reason to question it.

Biogen lowers 2023 profit outlook on costs of Reata purchase

Cambridge-based Biogen is cutting costs while broadening its focus to replace declining revenue from multiple sclerosis therapies, which made up more than half the drugmaker’s 2022 sales.

Moderna shares sink as company forecasts 2024 sales decline

The Cambridge-based vaccine maker sees revenue falling to about $4 billion next year, with sales growth resuming in 2025 as new vaccines hit the market.

Patients with sickle cell disease urge FDA to greenlight landmark gene-editing treatment

The treatment is administered with a single infusion and was created by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics, which has most of its employees in Mass.